Chong Kun Dang also enters low-intensity atorvastatin mkt
By Lee, Hye-Kyung | translator Kim, Jung-Ju
24.03.12 12:05:38
가나다라
0
Lipilou 5mg is approved… none are listed for reimbursement yet

Amid fierce competition in the hyperlipidemia drug market to develop 2nd generation ‘statin + ezetimibe’ combination drugs using low-strength statins, some low-dose atorvastatin products are also soon to enter the market.
On the 12th, the MFDS approved Chong Kun Dang's ‘Lipilou Tab 5mg.’ It is a 5 mg low-strength single tablet that contains atorvastatin calcium trihydrate.
This is the second single low-dose atorvastatin drug to be approved after Yuhan Corp’s 'Atorvastatin 5mg' in May last year.
Chong Kun Dang owns 3 ‘Lipilouzet Tab’ combination drugs that contain atorvastatin and ezetimibe. The three contain the same dose of ezetimibe of 10 mg, with different doses
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)